» Articles » PMID: 27878235

Accelerated Cell Cycle Progression of Human Regulatory T cell-like Cell Line Caused by Continuous Exposure to Asbestos Fibers

Overview
Journal Int J Oncol
Specialty Oncology
Date 2016 Nov 24
PMID 27878235
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Asbestos exposure causes malignant tumors such as lung cancer and malignant mesothelioma. Based on our hypothesis in which continuous exposure to asbestos of immune cells cause reduction of antitumor immunity, the decrease of natural killer cell killing activity with reduction of NKp46 activating receptor expression, inhibition of cytotoxic T cell clonal expansion, reduced CXCR3 chemokine receptor expression and production of interferon-γ production in CD4+ T cells were reported using cell line models, freshly isolated peripheral blood immune cells from health donors as well as asbestos exposed patients such as pleural plaque and mesothelioma. In addition to these findings, regulatory T cells (Treg) showed enhanced function through cell-cell contact and increased secretion of typical soluble factors, interleukin (IL)-10 and transforming growth factor (TGF)-β, in a cell line model using the MT-2 human polyclonal T cells and its sublines exposed continuously to asbestos fibers. Since these sublines showed a remarkable reduction of FoxO1 transcription factor, which regulates various cell cycle regulators in asbestos-exposed sublines, the cell cycle progression in these sublines was examined and compared with that of the original MT-2 cells. Results showed that cyclin D1 expression was markedly enhanced, and various cyclin-dependent kinase-inhibitors were reduced with increased S phases in the sublines. Furthermore, the increase of cyclin D1 expression was regulated by FoxO1. The overall findings indicate that antitumor immunity in asbestos-exposed individuals may be reduced in Treg through changes in the function and volume of Treg.

Citing Articles

Zbtb20 identifies and controls a thymus-derived population of regulatory T cells that play a role in intestinal homeostasis.

Krzyzanowska A, Haynes Ii R, Kovalovsky D, Lin H, Osorio L, Edelblum K Sci Immunol. 2022; 7(71):eabf3717.

PMID: 35522722 PMC: 9709958. DOI: 10.1126/sciimmunol.abf3717.


The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review.

Desage A, Karpathiou G, Peoch M, Froudarakis M Cancers (Basel). 2021; 13(13).

PMID: 34206956 PMC: 8269097. DOI: 10.3390/cancers13133205.


The Effects of Asbestos Fibers on Human T Cells.

Kumagai-Takei N, Lee S, Srinivas B, Shimizu Y, Sada N, Yoshitome K Int J Mol Sci. 2020; 21(19).

PMID: 32977478 PMC: 7584019. DOI: 10.3390/ijms21196987.


Inflammatory Alteration of Human T Cells Exposed Continuously to Asbestos.

Kumagai-Takei N, Yamamoto S, Lee S, Maeda M, Masuzzaki H, Sada N Int J Mol Sci. 2018; 19(2).

PMID: 29419731 PMC: 5855726. DOI: 10.3390/ijms19020504.


Search for biomarkers of asbestos exposure and asbestos-induced cancers in investigations of the immunological effects of asbestos.

Matsuzaki H, Kumagai-Takei N, Lee S, Maeda M, Sada N, Hatayama T Environ Health Prev Med. 2017; 22(1):53.

PMID: 29165150 PMC: 5664581. DOI: 10.1186/s12199-017-0661-4.

References
1.
Nishikawa H, Sakaguchi S . Regulatory T cells in tumor immunity. Int J Cancer. 2010; 127(4):759-67. DOI: 10.1002/ijc.25429. View

2.
Miura Y, Nishimura Y, Katsuyama H, Maeda M, Hayashi H, Dong M . Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells. Apoptosis. 2006; 11(10):1825-35. DOI: 10.1007/s10495-006-9235-4. View

3.
PARKES W . Asbestos-related disorders. Br J Dis Chest. 1973; 67(4):261-300. DOI: 10.1016/s0007-0971(73)80001-4. View

4.
Matsuzaki H, Lee S, Maeda M, Kumagai-Takei N, Nishimura Y, Otsuki T . FoxO1 regulates apoptosis induced by asbestos in the MT-2 human T-cell line. J Immunotoxicol. 2016; 13(5):620-7. DOI: 10.3109/1547691X.2016.1143539. View

5.
Lee S, Matsuzaki H, Kumagai-Takei N, Yoshitome K, Maeda M, Chen Y . Silica exposure and altered regulation of autoimmunity. Environ Health Prev Med. 2014; 19(5):322-9. PMC: 4166593. DOI: 10.1007/s12199-014-0403-9. View